These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25655624)

  • 1. Amyloid imaging in dementia: contribution or confusion?
    Frey KA
    J Nucl Med; 2015 Mar; 56(3):331-2. PubMed ID: 25655624
    [No Abstract]   [Full Text] [Related]  

  • 2. Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging.
    Machulla HJ
    J Nucl Med; 2015 Sep; 56(9):1466-7. PubMed ID: 26159584
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: Alzheimer Disease: Approaches to Early Diagnosis and High-Accuracy Imaging.
    Frey KA
    J Nucl Med; 2015 Sep; 56(9):1467. PubMed ID: 26159591
    [No Abstract]   [Full Text] [Related]  

  • 4. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid imaging: liberal or conservative? Let the data decide.
    Jagust WJ
    Arch Neurol; 2011 Nov; 68(11):1377-8. PubMed ID: 21747005
    [No Abstract]   [Full Text] [Related]  

  • 6. [Amyloid PET imaging with [18F]AV-45].
    Tateno A; Okubo Y
    Nihon Rinsho; 2011 Oct; 69 Suppl 8():561-4. PubMed ID: 22787851
    [No Abstract]   [Full Text] [Related]  

  • 7. Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions.
    Pearson SD; Ollendorf DA; Colby JA
    JAMA Intern Med; 2014 Jan; 174(1):133-4. PubMed ID: 24081022
    [No Abstract]   [Full Text] [Related]  

  • 8. Amyloid PET/MRI in the differential diagnosis of dementia.
    Vercher-Conejero JL; Rubbert C; Kohan AA; Partovi S; O'Donnell JK
    Clin Nucl Med; 2014 Jun; 39(6):e336-9. PubMed ID: 23856830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking brain amyloid-β in presymptomatic Alzheimer's disease.
    Jagust W
    Lancet Neurol; 2012 Dec; 11(12):1018-20. PubMed ID: 23137951
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.
    Zannas AS; Doraiswamy PM; Shpanskaya KS; Murphy KR; Petrella JR; Burke JR; Wong TZ
    Neurocase; 2014 Aug; 20(4):466-73. PubMed ID: 23672654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Centers for Medicare & Medicaid Services and amyloid-β positron emission tomography for Alzheimer disease.
    Steinbrook R
    JAMA Intern Med; 2014 Jan; 174(1):135. PubMed ID: 24081002
    [No Abstract]   [Full Text] [Related]  

  • 12. An imaging agent for amyloid.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):54-5. PubMed ID: 22777304
    [No Abstract]   [Full Text] [Related]  

  • 13. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
    Carome M; Wolfe S
    JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
    [No Abstract]   [Full Text] [Related]  

  • 14. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
    Yang L; Rieves D; Ganley C
    N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
    Shea YF; Ha J; Lee SC; Chu LW
    Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of PET-imaging probes of β-amyloid plaques.
    Koo J; Byun Y
    Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive agent approved as part of Alzheimer disease workup.
    Thompson CA
    Am J Health Syst Pharm; 2012 May; 69(10):818. PubMed ID: 22555074
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approves 18F-florbetapir PET agent.
    J Nucl Med; 2012 Jun; 53(6):15N. PubMed ID: 22661593
    [No Abstract]   [Full Text] [Related]  

  • 20. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.